Literature DB >> 16015178

Significance of a glenoid fossa approach for management of extensive lesions in the lateral skull base.

Yi Zixiang1, Zhang Rong, Cheng Jinmei, Lin Chang, Lin Gongbiao.   

Abstract

OBJECTIVE: This article is designed to relate our experiences with a glenoid fossa approach for exposing the outer border of extensive lesions in the lateral skull base.
MATERIALS AND METHODS: In this series, there were five large paragangliomas with the longest diameter of 6.5 cm in length, one large jugular schwannoma with extratemporal components, and one severe case of petromastoiditis with otogenic pachymeningitis, edema of the temporal lobe, and mental disorder. All lesions of these cases were treated via a glenoid fossa approach combined with other reasonable approaches.
RESULTS: The glenoid fossa approach resulted in crucial advantages: 1) it effectively exposes the outer border of extensive lesions in the lateral skull base; 2) it provides safe distal control of the facial nerve and internal carotid artery in the skull base; 3) it obviates the need for anterior transposition or rerouting of the facial nerve; and 4) it obviates sacrifice of the intact middle ear or section the mandibular condyle. There is no postoperative mandibular dysfunction because the mandibular articular capsule and articular tubercle are kept intact.
CONCLUSION: On the basis of our experiences, the glenoid fossa approach is a safe, quick, and useful design for adequate exposure of the outer border of extensive lesions in lateral skull base surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16015178     DOI: 10.1097/01.mao.0000178129.43612.46

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  1 in total

1.  Middle infratemporal fossa less invasive approach for radical resection of parapharyngeal tumors: surgical microanatomy and clinical application.

Authors:  Yoichi Nonaka; Takanori Fukushima; Kentaro Watanabe; Jun Sakai; Allan H Friedman; Ali R Zomorodi
Journal:  Neurosurg Rev       Date:  2015-07-11       Impact factor: 3.042

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.